Royce & Associates LP Reduces Position in Omnicell, Inc. $OMCL

Royce & Associates LP lessened its stake in shares of Omnicell, Inc. (NASDAQ:OMCL) by 70.9% in the fourth quarter, HoldingsChannel.com reports. The firm owned 5,654 shares of the company’s stock after selling 13,763 shares during the quarter. Royce & Associates LP’s holdings in Omnicell were worth $256,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in OMCL. AQR Capital Management LLC boosted its stake in shares of Omnicell by 42.1% during the first quarter. AQR Capital Management LLC now owns 17,936 shares of the company’s stock valued at $627,000 after purchasing an additional 5,311 shares during the period. Empowered Funds LLC raised its holdings in shares of Omnicell by 14.3% during the first quarter. Empowered Funds LLC now owns 9,953 shares of the company’s stock valued at $348,000 after acquiring an additional 1,243 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Omnicell by 4.1% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 124,047 shares of the company’s stock valued at $4,337,000 after acquiring an additional 4,866 shares in the last quarter. Jane Street Group LLC raised its holdings in shares of Omnicell by 201.5% during the first quarter. Jane Street Group LLC now owns 163,664 shares of the company’s stock valued at $5,722,000 after acquiring an additional 109,382 shares in the last quarter. Finally, Creative Planning raised its holdings in shares of Omnicell by 16.7% during the second quarter. Creative Planning now owns 9,390 shares of the company’s stock valued at $276,000 after acquiring an additional 1,347 shares in the last quarter. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Omnicell Price Performance

OMCL stock opened at $44.14 on Monday. The firm has a 50-day moving average of $38.99 and a 200 day moving average of $41.12. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.50 and a quick ratio of 1.29. The company has a market cap of $2.01 billion, a P/E ratio of 100.32, a PEG ratio of 1.14 and a beta of 0.97. Omnicell, Inc. has a 1 year low of $26.84 and a 1 year high of $55.00.

Omnicell (NASDAQ:OMCL) last posted its quarterly earnings data on Tuesday, April 28th. The company reported $0.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.33 by $0.22. The business had revenue of $309.88 million during the quarter, compared to the consensus estimate of $304.02 million. Omnicell had a return on equity of 4.00% and a net margin of 1.67%.The firm’s quarterly revenue was up 14.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.26 earnings per share. Omnicell has set its FY 2026 guidance at 1.800-2.000 EPS and its Q2 2026 guidance at 0.400-48.000 EPS. On average, sell-side analysts forecast that Omnicell, Inc. will post 1.31 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the company. Piper Sandler restated an “overweight” rating and set a $49.00 target price (down from $63.00) on shares of Omnicell in a report on Friday, February 6th. Benchmark reaffirmed a “buy” rating on shares of Omnicell in a research note on Friday, March 13th. Zacks Research raised shares of Omnicell from a “hold” rating to a “strong-buy” rating in a research note on Friday, May 1st. Wells Fargo & Company increased their price target on shares of Omnicell from $52.00 to $55.00 and gave the stock an “overweight” rating in a research note on Thursday, April 23rd. Finally, Wall Street Zen raised shares of Omnicell from a “buy” rating to a “strong-buy” rating in a research note on Sunday, May 10th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, Omnicell currently has an average rating of “Buy” and a consensus price target of $59.86.

Insiders Place Their Bets

In other Omnicell news, EVP Corey J. Manley sold 7,405 shares of the stock in a transaction on Monday, March 16th. The stock was sold at an average price of $34.69, for a total value of $256,879.45. Following the completion of the transaction, the executive vice president owned 96,717 shares in the company, valued at approximately $3,355,112.73. This represents a 7.11% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Nnamdi Njoku sold 3,090 shares of the stock in a transaction on Monday, May 18th. The stock was sold at an average price of $43.22, for a total value of $133,549.80. Following the completion of the transaction, the executive vice president owned 154,785 shares of the company’s stock, valued at approximately $6,689,807.70. This trade represents a 1.96% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders sold 15,520 shares of company stock valued at $607,610. 2.92% of the stock is owned by corporate insiders.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.